Stockreport

IGC Pharma Announces Equity Analyst Coverage by Ascendiant with a “Buy” Recommendation and $3.00 Price Target

IGC Pharma, Inc.  (IGC) 
NASDAQ:AMEX Investor Relations: igcinc.us/investor-center/overview
PDF POTOMAC, Md.--(BUSINESS WIRE)--IGC Pharma, Inc. (“IGC Pharma,” “IGC,” or the “Company”) (NYSE American: IGC) announces that Ascendiant Capital Markets LLC (Ascendian [Read more]